brain tumor
Conditions
Interventions
Remimazolam is administered as a sedative in awake craniotomy
Propofol is administered as a sedative in awake craniotomy
Sponsors
Sapporo Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who undergo awake craniotomy using asleep-awake-asleep procedure Patients whose ASA-PS is 1 or 2, indicating their physical status are good
Exclusion criteria
Exclusion criteria: Patients diagnosed as severe cognitive dysfunction in preoperative period Patients who have allergy for propofol, remimazolam and flumazenil Patients who have severe hepatic dysfunction and/or renal dysfunction Patients determined as inappropriate to include by researcher of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time needed for emergence from general anesthesia | — |
Secondary
| Measure | Time frame |
|---|---|
| Time needed for extubation Time course of sedation score Time course of bispectral index Serum concentration of remimazolam Blood pressure, heart rate and SpO2 during general anesthesia Incidence of awake craniotomy failure Incidence of flumazenil administration Doses of sedatives at re-anesthetic induction Time needed for re-anesthetic induction | — |
Countries
Japan
Contacts
Public ContactTomohiro Chaki
Sapporo Medical University School of Medicine Department of Anesthesiology
Outcome results
None listed